Allakos Analyst Turns Bullish News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Allakos reports disappointing topline data from phase 2 trials for lirentelimab in atopic dermatitis and chronic spontaneous urticaria. Company undergoes restructuring to focus on AK006, extending cash runway into mid-2026.

Allakos incCraig patersonUrticaria activity scoreChief medical officerAllakos analyst turns bullishSignificant upside if study results areAfter disappointing data